Ixico plc, a London-based provider of specialty data analytics services, said that it has expanded its contract with an unidentified biopharma company to May 2021, adding €0.5 million (US$583,300) to the Alzheimer's disease-focused contract. The total contract value is now €1.3 million (US$1.5 million)